Used for gout for centuries, colchicine is known to be peculiarly toxic at high doses. A new understanding of its potential for poisoning, deliberate or otherwise, merits attention to its often-underestimated risks.

Among the revelations about gout treatment at this year’s meeting: Confusion among physicians about the definition of “control,” misunderstandings among gout patients about their own disease, and new drug options.

Beyond causing gout, uric acid appears to be on the verge of stepping into a far broader role. Collectively, numerous clinical and animal studies portray it as the central villain in the mystery that links hypertension, kidney failure, and diabetes.

New label changes about hepatic risks with the gout drug febuxostat (Uloric) and uncertainties about the new oral RA drug tofacitinib (Xeljanz) were on the agenda as the most important new drug issues arising this year, as FDA officials spoke at the American College of Rheumatology meeting.

(VIDEO) When treating gout, said a University of Pennsylvania researcher at the American College of Rheumatology meeting, remember that others may not monitor colchicine as carefully as you would.

Women with higher uric acid levels around and after menopause show less bone loss. What could this mean?

(AUDIO) African Americans are not treated as effectively for gout as Caucasians. In this recorded interview, Dr. Jasvinder Singh ponders the meaning of this disparity and gives advice about how doctors can assure the best treatment for gout in all ethnic groups.


Subscribe to
Please Wait 20 seconds or click here to close